

Female Sexual Dysfunction - Pipeline Review, H2 2019

<https://marketpublishers.com/r/FB289B00808EN.html>

Date: December 2019

Pages: 83

Price: US\$ 2,000.00 (Single User License)

ID: FB289B00808EN

Abstracts

Female Sexual Dysfunction - Pipeline Review, H2 2019

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Female Sexual Dysfunction - Pipeline Review, H2 2019, provides an overview of the Female Sexual Dysfunction (Women's Health) pipeline landscape.

Female sexual dysfunction occurs when a woman is not able to fully, healthily, and pleurably experience some or all of the various physical stages the body normally experiences during sexual activity. The predisposing factors include depression or anxiety, heart and blood vessel disease, liver or kidney failure and certain medications, such as antidepressants or high blood pressure medications. Treatment includes estrogen therapy.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Female Sexual Dysfunction - Pipeline Review, H2 2019, provides comprehensive information on the therapeutics under development for Female Sexual Dysfunction (Women's Health), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Female Sexual Dysfunction (Women's Health) pipeline guide also reviews of key players involved in therapeutic development for Female Sexual Dysfunction and features dormant and discontinued projects. The guide covers therapeutics under

Development by Companies/Universities/Institutes, the molecules developed by Companies in Pre-Registration, Phase II, Phase I, Phase 0, Preclinical, Discovery and Unknown stages are 3, 7, 1, 1, 6, 3 and 1 respectively.

Female Sexual Dysfunction (Women's Health) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

The pipeline guide provides a snapshot of the global therapeutic landscape of Female Sexual Dysfunction (Women's Health).

The pipeline guide reviews pipeline therapeutics for Female Sexual Dysfunction (Women's Health) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Female Sexual Dysfunction (Women's Health) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Female Sexual Dysfunction (Women's Health) therapeutics based on mechanism of action (MoA), drug target, route of

administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Female Sexual Dysfunction (Women's Health)

REASONS TO BUY

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Female Sexual Dysfunction (Women's Health).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Female Sexual Dysfunction (Women's Health) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Contents

- Introduction
- Global Markets Direct Report Coverage
- Female Sexual Dysfunction - Overview
- Female Sexual Dysfunction - Therapeutics Development Pipeline Overview
- Pipeline by Companies
- Products under Development by Companies
- Female Sexual Dysfunction - Therapeutics Assessment
 - Assessment by Target
 - Assessment by Mechanism of Action
 - Assessment by Route of Administration
 - Assessment by Molecule Type
- Female Sexual Dysfunction - Companies Involved in Therapeutics Development
 - Applied Biology Inc
 - Callitas Therapeutics Inc
 - Can-Fite BioPharma Ltd
 - Dare Bioscience Inc
 - Emotional Brain BV
 - EndoCeutics Inc
 - Fabre-Kramer Pharmaceuticals Inc
 - H. Lundbeck AS
 - Harrow Health Inc
 - Ivix Ltd
 - Kuhnle Pharmaceutical Co Ltd
 - M et P Pharma AG
 - Pivot Pharmaceuticals Inc
 - Re-Pharm Ltd
 - S1 Biopharma Inc
 - TherapeuticsMD Inc
- Female Sexual Dysfunction - Drug Profiles
 - (buspirone hydrochloride + testosterone) - Drug Profile
 - Product Description
 - Mechanism Of Action
 - R&D Progress
 - (sildenafil citrate + testosterone) - Drug Profile
 - Product Description
 - Mechanism Of Action

R&D Progress

AB-101 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BP-101 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

estradiol - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

FKW-00GA - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

gepirone hydrochloride ER - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

KI-1120 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

lidocaine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

prasterone - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PVT-005 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PVT-011 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

S1B-3006 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

S1B-307 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

sildenafil citrate - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SIP-104 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule for Sexual Dysfunction - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Agonize Estrogen Receptor for Female Sexual Dysfunction - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Target A3AR for Sexual Dysfunction - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

tadalafil - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TBS-2 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

vortioxetine hydrobromide - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Female Sexual Dysfunction - Dormant Projects

Female Sexual Dysfunction - Discontinued Products

Female Sexual Dysfunction - Product Development Milestones

Featured News & Press Releases

Oct 30, 2019: Knight and TherapeuticsMD announce filing of new drug submission for Joyesta in Canada

Oct 28, 2019: Dare Bioscience and Strategic Science & Technologies announce presentation of positive findings from thermography clinical study of Sildenafil Cream, 3.6 % in healthy women at the Sexual Medicine Society of North America Conference

Oct 08, 2019: Mayfield Pharmaceuticals to Present update on lidocaine at the SVB Leerink New Treatments Focused on Women's Health Conference on October 10, 2019

Sep 24, 2019: TherapeuticsMD announces multiple presentations related to IMVEXXY at the 2019 Annual Meeting of the North American Menopause Society

Sep 12, 2019: Ovoca announces filing of marketing authorisation application with Russian Ministry of Health for BP-101

Jun 17, 2019: Dare Bioscience announces positive results in Thermography feasibility study with Sildenafil Cream, 3.6%, a potential therapy for female sexual arousal disorder

Apr 23, 2019: Ovoca Bio announced US and EU clinical development plans

Mar 25, 2019: Ovoca Bio Libicore (BP-101) meets primary/secondary endpoints in phase 3 trial for hypoactive sexual desire disorder ahead of time

Mar 18, 2019: Dare Bioscience to present update on Sildenafil Cream at 31st Annual ROTH Conference

Jan 04, 2019: S1 Biopharma announces expanded analysis of phase 2a data on Lorexys for treatment of hypoactive sexual desire disorder based on PGIC scale to be presented at 2019 ISSWSH/ISSM joint meeting

Dec 20, 2018: S1 Biopharma granted patents for Lorexys in Europe and Asia for treatment of hypoactive sexual desire disorder

Nov 29, 2018: Dare Bioscience announces initiation of content validity study for Sildenafil Cream, 3.6%, a potential therapy for female sexual arousal disorder

Nov 27, 2018: Dare Bioscience Announces Enrollment in Thermography Feasibility Study with Sildenafil Cream, 3.6%, a Potential Therapy for Female Sexual Arousal Disorder

Oct 04, 2018: AMAG Pharmaceuticals and Endoceutics announce presentation at the

2018 Annual Meeting of The North American Menopause Society on the effect of time since menopause, age and previous hormone therapy on the response to intravaginal prasterone

Sep 13, 2018: TherapeuticsMD announces commercial availability of Imvexxy 4 mcg

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List Of Tables

LIST OF TABLES

Number of Products under Development for Female Sexual Dysfunction, H2 2019
Number of Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019 (Contd..1), H2 2019
Number of Products by Stage and Target, H2 2019
Number of Products by Stage and Mechanism of Action, H2 2019
Number of Products by Stage and Route of Administration, H2 2019
Number of Products by Stage and Molecule Type, H2 2019
Female Sexual Dysfunction - Pipeline by Applied Biology Inc, H2 2019
Female Sexual Dysfunction - Pipeline by Callitas Therapeutics Inc, H2 2019
Female Sexual Dysfunction - Pipeline by Can-Fite BioPharma Ltd, H2 2019
Female Sexual Dysfunction - Pipeline by Dare Bioscience Inc, H2 2019
Female Sexual Dysfunction - Pipeline by Emotional Brain BV, H2 2019
Female Sexual Dysfunction - Pipeline by EndoCeutics Inc, H2 2019
Female Sexual Dysfunction - Pipeline by Fabre-Kramer Pharmaceuticals Inc, H2 2019
Female Sexual Dysfunction - Pipeline by H. Lundbeck AS, H2 2019
Female Sexual Dysfunction - Pipeline by Harrow Health Inc, H2 2019
Female Sexual Dysfunction - Pipeline by Ivix Ltd, H2 2019
Female Sexual Dysfunction - Pipeline by Kuhnle Pharmaceutical Co Ltd, H2 2019
Female Sexual Dysfunction - Pipeline by M et P Pharma AG, H2 2019
Female Sexual Dysfunction - Pipeline by Pivot Pharmaceuticals Inc, H2 2019
Female Sexual Dysfunction - Pipeline by Re-Pharm Ltd, H2 2019
Female Sexual Dysfunction - Pipeline by S1 Biopharma Inc, H2 2019
Female Sexual Dysfunction - Pipeline by TherapeuticsMD Inc, H2 2019
Female Sexual Dysfunction - Dormant Projects, H2 2019
Female Sexual Dysfunction - Dormant Projects, H2 2019 (Contd..1), H2 2019
Female Sexual Dysfunction - Discontinued Products, H2 2019

List Of Figures

LIST OF FIGURES

Number of Products under Development for Female Sexual Dysfunction, H2 2019

Number of Products under Development by Companies, H2 2019

Number of Products by Top 10 Targets, H2 2019

Number of Products by Stage and Top 10 Targets, H2 2019

Number of Products by Top 10 Mechanism of Actions, H2 2019

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2019

Number of Products by Routes of Administration, H2 2019

Number of Products by Stage and Routes of Administration, H2 2019

Number of Products by Molecule Types, H2 2019

Number of Products by Stage and Molecule Types, H2 2019

COMPANIES MENTIONED

Applied Biology Inc

Callitas Therapeutics Inc

Can-Fite BioPharma Ltd

Dare Bioscience Inc

Emotional Brain BV

EndoCeutics Inc

Fabre-Kramer Pharmaceuticals Inc

H. Lundbeck AS

Harrow Health Inc

Ivix Ltd

Kuhnle Pharmaceutical Co Ltd

M et P Pharma AG

I would like to order

Product name: Female Sexual Dysfunction - Pipeline Review, H2 2019

Product link: <https://marketpublishers.com/r/FB289B00808EN.html>

Price: US\$ 2,000.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/FB289B00808EN.html>